Workshop Report: COVAX Vaccine Safety Working Group: Developer Needs Workshop

by Dr Julia Granerod
21st October 2020 • comment

Priority List of COVID-19 Adverse events of special interest: Quarterly update 1

by Barbara Law
9th September 2020 • comment

Early and Advanced Stage Clinical Development Core Elements- Comparison of the Guidance and Considerations

by Paul Oloo
3rd September 2020 • comment

Preparing for Lassa vaccine clinical trials with targeted epidemiology studies

by CEPI
1st July 2020 • comment

Core Elements for Advanced Stage Clinical Trials of COVID-19 Vaccine Candidates: Aspects to Consider

by Amol Chaudhari
26th June 2020 • comment

Efficacy Endpoints in COVID-19 Vaccine Trials: SARS-CoV-2 Infection

by Amol Chaudhari & Edde Loeliger
25th June 2020 • comment

General Core Elements for Early Phase Clinical Trials of COVID-19 Vaccine Candidates: Aspects to Consider

by Amol Chaudhari
21st April 2020 • comment

Consensus considerations on the assessment of the risk of disease enhancement with COVID-19 vaccines:

by Coalition for Epidemic Preparedness Innovations (CEPI)

The SARS-CoV-2 pandemic presents an unprecedented challenge to global health with enormous health system, social and economic disruption and large numbers of deaths already experienced in many countries. Epidemiologic features confirm that ongoing spread to less affected areas is now a certainty.

20th March 2020 • comment

Priority List of Adverse Events of Special Interest: COVID-19

by Barbara Law , Miriam Sturkenboom

To maximize the value of vaccine safety data in clinical trials given their relatively limited sample size, it is essential to standardize their collection, presentation and analysis when possible.Given serious adverse events following immunization (AEFIs) are fortuitously rare, this need for globally accepted standard case definitions that allow for valid comparisons extend to individual case reports, surveillance systems, and retrospective epidemiologic studies.

5th March 2020 • comment